Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Gastroenterology

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/s1470-2045(14)70023-3